Orale Antikoagulanzien vom Cumarintyp

Zusammenfassung

Es wird ein Überblick über Pharmakologie und Indikationen zur Therapie mit Vitamin-K-Antagonisten gegeben sowie zur Therapiehandhabung mit Selbstkontrolle durch die Patienten.

Summary

A survey is given on pharmacology and indications for the treatment with vitamin K antagonists. The therapeutic handling and self control by the patient is described.

Schlüsselwörter

Vitamin-K-Antagonisten - Cumarinderivate - Thromboemboliederivate - Antikoagulanzien-Selbstkontrolle

Keywords

Vitamin K antagonists - cumarine derivatives - thromboembolism - self control of treatment with anticoagulants

• Literatur

• 1 Barthels M, von Depka M. Das Gerinnungskompendium. Stuttgart: Thieme; 2002
• 2 Bauer K A. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74: 94.
• 3 DIN 58911, Teil 1 Hämostaseologie. Kalibrierung von Meßverfahren. DIN-Taschenbuch 261 »Hämostaseologie«. Berlin: Beuth; 1996
• 4 Hirsh J. Guide to anticoagulant therapy, part 2: oral anticoagulants. Circulation 1994; 89: 1469.
• 5 Hirsh J. Oral anticoagulants: mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (Suppl. 04) 231S.
• 6 Hull R, Delmore T, Genton E. et al. Warfarin sodium versus low dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
• 7 Hull R, Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 1982; 3016: 189.
• 8 Kearon C, Ginsberg JS, Kovacs MJ. et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
• 9 Kemkes-Matthes B, Matzdorff A, Heidt M. et al. Initialphase der oralen Antikoagulanzientherapie: Vergleich verschiedener Dosierungen von Warfarin und Phenprocoumon. Hämostaseologie 2002; 22: 87-91.
• 10 Lagerstedt CI, Fagher BO, Albrechtsson U. et al. Need for long term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 1985; 2: 515.
• 11 Man-Son-Hing M, Nichol G, Lau A. et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-85.
• 12 Mok CK, Boey J, Wang R. et al. Warfarin versus dipyridamole – aspirin and pentoxyphylline – aspirin for the prevention of proshtetic heart valve thromboembolism: a prospective clinical trial. Circulation 1985; 72: 1059.
• 13 Müller-Beißenhirz W, Deickert F, Lang H. et al. Selbstkontrolle der oralen Antikoagulation: Standortbestimmung. Hämostaseologie 1998; 18: 84-8.
• 14 Petersen D, Barthels M. Die artefiziell manipulierte Krankheit durch heimliche Einnahme des oralen Antikoagulans Phenprocoumon: Untersuchung an 16 eigenen Fällen. Med Klin 1995; 90: 277.
• 15 Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost 2004; 2: 849-60.
• 16 Ridker PM, Goldhaber SZ, Danielson E. et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
• 17 Sixty Plus Reinfarction Study Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989-93.
• 18 Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147.
• 19 Turpie AG, Gent M, Laupacis A. et al. Aspirin and warfarin after heart-valve replacement: a comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524.
• 20 Watzke HH, Forberg E, Scolba G. et al. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000; 83: 661-5.
• 21 Wawrzynska L, Tomkowski WZ, Przedlacki J. et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxs of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33: 64-7.
• 22 Witt I, Beeser H, Lang H. et al. Thromboplastinzeit und INR: Standardisierung der Methode, Anwendung zur Kontrolle der oralen Antikoagulantientherapie und als Globaltest der plasmatischen Gerinnung – Standortbestimmung. J Lab Med 1996; 20: 443.